Migraine, the menopause and hormone replacement therapy: a clinical review

E Anne MacGregor

Overview
In contrast to the relatively stable hormone profile during the middle reproductive years, the perimenopause is marked by erratic fluctuations of oestrogen and progesterone. By the late perimenopause, oestrogen levels can reach high magnitudes. Given the association between migraine and oestrogen ‘withdrawal’ it is not surprising that this stage of life is often accompanied by worsening migraine, which persists until oestrogen levels plateau post-menopause.

This paper reviews the effects that menopause and hormone replacement therapy (HRT) have on headache and migraine and considers the data on the risk of ischaemic stroke in HRT users with migraine. This evidence will be used to support practical guidance on the management of women with migraine wishing to use HRT.

Search strategy
A MEDLINE search from 1950 to April 2007 using the search terms ‘headache’, ‘migraine’, ‘menopause’, ‘hormone replacement therapy’, ‘perimenopause’, ‘progestogen’, ‘progestosterone’, ‘(o)estrogen’, ‘(o)estradiol’ and ‘selective (o)estrogen receptor modulators’ identified 100 publications, which were scrutinised for relevancy to this review.

In addition, references from the author’s own files, a hand-search of the journals Cephalalgia and Headache, and peer-reviewed presentations at international congresses were considered.

Effect of the menopause on headache and migraine
Headache is a common but under-reported complaint in perimenopausal women. A study of 74 women attending a London menopause clinic reported that in the preceding 3 months, 57% had experienced headache and 29% had experienced migraine. Migraine was associated with significant disability, with 80% of women affected reporting attacks more often than once a month, 75% reporting severe attacks and 50% reporting attacks lasting longer than 1 day.

In 1000 women attending a Leicester menopause clinic, 85% reported recurrent headache of which 73% reported headache more often than once a month. Migraine was reported by 24% of women.

In a retrospective questionnaire of 29 postmenopausal women with tension-type headache, six women (21%) reported by 24% of women.

There are few data regarding the effect of menopause on migraine aura, although the clinical impression is one of little change.

Type of menopause is important, with a lower prevalence of migraine following physiological menopause compared to surgical menopause (Table 1).

<table>
<thead>
<tr>
<th>Type of Menopause</th>
<th>Migraine Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural Menopause</td>
<td>10.5%</td>
</tr>
<tr>
<td>Surgical Menopause</td>
<td>16.7%</td>
</tr>
</tbody>
</table>

Some studies suggest that a history of worsening migraine at menopause is a factor in predicting worsening migraine with HRT.3,9 However, it is not known whether HRT is associated with increased incidence of headache and migraine or whether HRT is initiated because of headache.
Oestrogen
Regimen
Oestrogen replacement should be given continuously as oestrogen ‘withdrawal’ migraine can occur, in addition to return of menopause symptoms, with cyclical regimens.\textsuperscript{12}

Type of oestrogen
There are no data on the differential effects of human or equine oestrogens on migraine.

Route of delivery
Non-oral routes are less likely to have a detrimental effect on migraine than oral formulations of oestrogen replacement (Table 3).\textsuperscript{13,14} This is probably the result of the more stable serum hormone levels associated with non-oral routes.\textsuperscript{15} If oral preparations are favoured, tibolone may be the preferred option.\textsuperscript{16}

Dose
Oestrogen replacement therapy can have an adverse effect on migraine aura as evidenced by a report of 10 women seen in an ophthalmology clinic who were using transdermal oestrogen patches 50 µg daily, of whom six had a history of migraine (three migraine with aura, three migraine without aura) before using replacement therapy.\textsuperscript{17} All six women developed increased headache severity and accompanying visual scintillations. One patient with no previous history of migraine developed visual scintillations with no accompanying headache. Withdrawal of oestrogens and additional prophylactic antimigraine therapy led to marked improvement in all women, with complete cessation of migraine in four patients.

However, complete withdrawal of HRT may be unnecessary, as case reports on four women developing migraine aura following initiation of HRT showed that, in all cases, aura resolved with either a reduction in oestrogen dose or change in route of delivery of oestrogen.\textsuperscript{18}

Progestogen
Regimen
Continuous combined HRT appears to be better tolerated by migraineurs than cyclical combined HRT.\textsuperscript{19}

Type, route of delivery and dose of progestogen
There are no data regarding the effect on migraine of different types, routes of delivery or doses of progestogens used for HRT. However, progestogen intolerance resulting in bleeding problems, fluid retention, headache and negative mood adversely affects compliance.\textsuperscript{20}

---

Table 1 The effect of menopause on migraine

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Sample size</th>
<th>Outcome</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neri et al. (1993)\textsuperscript{4}</td>
<td>Retrospective questionnaire</td>
<td>47 postmenopausal women with migraine</td>
<td>Improvement or complete remission: 51%, Unchanged: 17%, Worsened: 15%, New onset: 17%</td>
<td>*p = 0.003 (vs physiological menopause)</td>
</tr>
<tr>
<td>Granella et al. (1993)\textsuperscript{7}</td>
<td>Retrospective observational study</td>
<td>116 physiological menopause</td>
<td>Improvement or complete remission: 24.1%, Unchanged: 43.1%, Worsened: 27.6%, New onset: 5.2%</td>
<td>*p &lt; 0.01</td>
</tr>
<tr>
<td>Mueller (2000)\textsuperscript{9}</td>
<td>Retrospective questionnaire</td>
<td>168 postmenopausal women</td>
<td>Improvement or complete remission: 24.4%, Unchanged: 39.8%, Worsened: 35.7%, New onset: NR</td>
<td>NR</td>
</tr>
<tr>
<td>Martin et al. (2003)\textsuperscript{8}</td>
<td>Randomised placebo-controlled study</td>
<td>9 medical menopause with 1 month goserelin followed by 2 months goserelin + add-back oestradiol</td>
<td>37% reduction in headache index during oestradiol treatment</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12 medical menopause with 1 month goserelin followed by 2 months goserelin + placebo</td>
<td>No change</td>
<td>**p = 0.025</td>
</tr>
</tbody>
</table>

NR, not reported.

---

Table 2 The effect of hormone replacement therapy on migraine: users versus never-users

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Sample size</th>
<th>OR</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Misakian et al. (2003)\textsuperscript{11}</td>
<td>Population-based questionnaire</td>
<td>Women's Health Study of 21,788</td>
<td>1.42 (95% CI 1.24–1.62)</td>
<td>ORs were similar for oestrogen-only and combined oestrogen-progestogen HRT</td>
</tr>
<tr>
<td>Aegidius et al. (2007)\textsuperscript{10}</td>
<td>Cross-sectional questionnaire</td>
<td>Nord-Trøndelag Health Study of 29,679</td>
<td>1.6 (95% CI 1.4–1.9)</td>
<td>Oestrogen-only OR 1.7 (95% CI 1.4–2.0); combined oestrogen-progestogen OR 1.7 (95% CI 1.2–2.4)</td>
</tr>
</tbody>
</table>

HRT, hormone replacement therapy; OR, odds ratio.
Risk of cardiovascular disease in women with migraine

Migraine with aura is a risk factor for ischaemic stroke.21–30 Most of these studies assessed young women with ischaemic stroke and there are few data on older populations. More recent studies suggest that migraine with aura is also a risk factor for cardiovascular disease. Analysis of 5125 women aged over 45 years participating in the prospective cohort Women’s Health Study showed that only active migraine with aura at baseline, and not a past history, was a risk factor for cardiovascular disease associated with use of HRT.34 There is evidence from controlled trials to support earlier observations that HRT initiated during the perimenopause is not associated with increased risk of stroke and cardiovascular disease and is more likely to have beneficial effects.35–37

On this basis there are theoretical benefits for women with migraine wishing to start HRT in the perimenopause. However, there are no data on risk of cardiovascular disease associated with new onset of migraine aura in women using HRT.

Risk of cardiovascular disease in women using HRT

Concerns regarding an increased risk of cardiovascular disease associated with use of HRT are unjustified as they relate to an atypical population of postmenopausal women starting HRT.33 There is evidence from controlled trials to support earlier observations that HRT initiated during the perimenopause is not associated with increased risk of stroke and cardiovascular disease and is more likely to have beneficial effects.35–37

On this basis there are theoretical benefits for women with migraine wishing to start HRT in the perimenopause. However, there are no data on risk of cardiovascular disease associated with new onset of migraine aura in women using HRT.

Risk of cardiovascular disease in women with migraine using HRT

There are few studies assessing the risk of ischaemic stroke or myocardial infarction in women with migraine using HRT. The Women’s Health Study did not find an association between these conditions and use of postmenopausal hormone therapy in women with migraine with or without aura.30

Alternatives to HRT

Reviews and recommendations for effective alternatives to HRT in women with vasomotor symptoms support the use of fluoxetine, paroxetine, venlafaxine or gabapentin.38,39 Evidence of efficacy for migraine prophylaxis has been shown for fluoxetine and venlafaxine.40–43 Initial exacerbation of migraine in the first few weeks of treatment is an effect of some selective serotonin reuptake inhibitors (SSRIs) so it is important not to stop treatment for these adverse effects.
too early. Gabapentin can also be used for migraine prophylaxis, although evidence of efficacy is far from robust. The most common adverse events reported are dizziness and sedation.

The efficacy and safety of complementary therapies have not been demonstrated, although phyto-oestrogens are widely used for vasomotor symptom control. One randomised controlled trial suggests some efficacy in menstrual migraine but, conversely, there is one case report of new-onset migraine following initiation of isoflavone supplements.

There are no data on the effect of selective oestrogen receptor modulators (SERMS) on postmenopausal women with migraine, although prescription-event monitoring has been used to assess safety in 13,987 patients for whom useful information was available. Flushing was the most common specific adverse event reported. Headache/migraine was the third most frequently reported adverse drug reaction associated with starting raloxifene and the fifth most frequently reported reason for stopping the drug. Although these data are limited, they do not support the use of SERMS as an alternative to HRT in women with migraine.

**Practical recommendations for use of HRT (Box 1)**

Headache in perimenopausal women is most likely to be a reflection of the background prevalence of migraine in the different age groups. Prospective data do not support an association between migraine with or without aura and ischaemic stroke in postmenopausal women, but do support an association between migraine with aura and increased risk of ischaemic stroke and myocardial infarction. Given the association between aura and cardiovascular risk factors, it is important to evaluate these risk factors and treat them appropriately.

There is no evidence that the treatment of menopausal symptoms in women with migraine should differ from standard recommendations, including use of HRT. There are theoretical and clinical benefits to non-oral oestrogen replacement for all women wishing to use HRT. For women with migraine, the evidence suggests that low-dose non-oral preparations of oestradiol should be recommended as first choice. Continuous progestogens are better tolerated than cyclical progestogens. Changing the type of progestogen can help, as side effects are fewer with progestrone derivatives such as medroxyprogesterone acetate and dydrogesterone rather than with testosterone derivatives such as norethisterone. Drosperone is a more recent well-tolerated option although it is currently only available as an oral preparation combined with oestrogen. Changing route from oral to transdermal progestogen may also be effective, as may reducing the course of cyclical progestogens to only 7–10 days per month, although the latter is potentially associated with increased risk of endometrial hyperplasia. Natural progesterone is available as suppositories, micronised tablets and vaginal gel, although the availability of these different formulations varies worldwide. Sedation is a common adverse effect of natural progesterone. A well-tolerated option is the levonorgestrel-releasing intrauterine system used with oestrogen supplementation. Occasionally progestogen adverse effects are sufficiently bothersome for a woman to choose to discontinue progestogens. In these cases specialist referral is appropriate for regular endometrial assessment.

Although migraine attacks may increase when HRT is initiated, there is usually improvement with continued use. Any new-onset headache should be carefully evaluated for secondary causes, as although migraine may occasionally develop for the first time during the perimenopause, it is unusual for migraine to begin post-menopause.

There are no data regarding risk associated with developing a first attack of migraine with aura when using HRT. There is the concern that transient ischaemic attacks (TIAs) may be misdiagnosed as aura since it is not always easy to distinguish between the two conditions. On a practical basis, once TIAs have been excluded, the dose and route of delivery of oestrogen replacement should be assessed to provide the lowest effective dose necessary to control menopausal symptoms.

For symptomatic and prophylactic treatment of migraine standard strategies apply. Given the association between migraine aura and increased risk factors for cardiovascular disease, these should be assessed and managed accordingly. Unless the woman’s cardiovascular risk profile contraindicates triptans, there is no evidence that triptan use is associated with increased risk of stroke or cardiovascular disease.

**Conclusions**

Headache and migraine are common symptoms of the menopause but are often under-reported. Perimenopausal women should routinely be asked about headache and migraine so that they can be offered appropriate advice. This should include optimal symptomatic treatment for attacks and strategies for prevention. In women with additional menopausal symptoms, management may include use of continuous HRT via a non-oral route, using the lowest effective dose necessary to control symptoms.

**Statements on funding and competing interests**

**Funding** None identified.

**Competing interests** None identified.

**References**
